Odyssey Therapeutics, Inc. Common Stock (ODTX)

Odyssey Therapeutics, Inc. Common Stock (ODTX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $871M; returns 1 day +2.7%, 1 week +14.2%.

Odyssey Therapeutics (ODTX) is a clinical-stage biopharmaceutical company that debuted on the Nasdaq in May 2026, raising approximately $304 million in an upsized IPO and concurrent private placement. Founded by serial biotech entrepreneur Dr. Gary Glick, the company focuses on precision immunomodulators for autoimmune and inflammatory diseases.

Groups ODTX belongs to

• Biotechnology
• Recent IPOs
• Clinical Stage Biopharma
• Autoimmune Diseases
• Pharmaceuticals
• Precision Medicine
• Artificial Intelligence
• Drug Discovery
• Healthcare
• Clinical Stage
• Machine Learning
• Chronic Inflammatory Diseases
• Gastroenterology

ODTX financial model: income statement, cash flow and balance sheet